Premium
Is it becoming or coming of age
Author(s) -
Cordeiro M.F.
Publication year - 2015
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2015.0228
Subject(s) - neuroprotection , medicine , neurodegeneration , glaucoma , clinical trial , neuroscience , disease , intensive care medicine , ophthalmology , psychology , pharmacology
Summary The realisation that lowering IOP is unable to prevent progressive vision loss in all glaucoma patients, has led to investigation of neuroprotection as an alternative or additional treatment option. Neuroprotection has gained renewed interest recently as a therapeutic approach to prevent neuronal degeneration and loss of function in glaucoma. Although confirmation of neuroprotective effects by randomized clinical trials is needed, there is now a demonstration of positive non‐ IOP dependent effects in the Lo GTS study. Furthermore, it has been proposed as a treatment strategy in other ocular diseases, such as AMD . Neuroprotection has been advocated for many years in neurodegeneration. Indeed, the therapies that have been suggested in Alzheimer's and Parkinson's Disease are similar to those investigated in ophthalmology. This talk will review the evidence for neuroprotection that led to our assessment of its role in glaucoma now and its application as treatment strategy.